Hims & Hers Stock Surges on Novo Nordisk GLP-1 Deal

In a shocking twist, Hims & Hers and Novo Nordisk have ended their bitter GLP-1 battle, paving the way for...

09/03/2026

4 views

Novo Nordisk Stock Tumbles After CagriSema Trial Setback

Novo Nordisk's next big obesity hope, CagriSema, just fell short in a crucial head-to-head trial against a rival powerhouse—triggering a...

26/02/2026

2 views

Novo Nordisk kicked off 2026 with a blockbuster oral obesity pill launch, but lawsuits, disappointing guidance, and fierce competition have...

11/02/2026

4 views

When Novo Nordisk's CEO talks about Medicare finally covering obesity drugs, he sees a potential flood of 15 million new...

11/02/2026

3 views

Novo Nordisk just got its Wegovy pill approved – a potential game-changer after a brutal year. But with Eli Lilly...

01/01/2026

4 views

Novo Nordisk just scored FDA approval for the first obesity pill, sending its shares soaring while Eli Lilly dipped. But...

23/12/2025

2 views